Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.485
-0.125 (-7.76%)
Mar 6, 2026, 1:18 PM EST - Market open
Metagenomi Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Metagenomi Therapeutics stock have an average target of 9.25, with a low estimate of 7.00 and a high estimate of 12. The average target predicts an increase of 522.90% from the current stock price of 1.49.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 19, 2025.
Analyst Ratings
The average analyst rating for Metagenomi Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +371.38% | Aug 19, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +640.74% | Aug 15, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +708.08% | Aug 14, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +708.08% | May 15, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $20 → $16 | Buy | Maintains | $20 → $16 | +977.44% | May 14, 2025 |
Financial Forecast
Revenue This Year
28.25M
from 52.30M
Decreased by -45.98%
Revenue Next Year
22.21M
from 28.25M
Decreased by -21.36%
EPS This Year
-2.38
from -2.36
EPS Next Year
-1.84
from -2.38
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 31.5M | 36.8M | ||||
| Avg | 28.2M | 22.2M | ||||
| Low | 25.6M | 15.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -39.8% | 30.1% | ||||
| Avg | -46.0% | -21.4% | ||||
| Low | -51.1% | -43.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.33 | -1.42 | ||||
| Avg | -2.38 | -1.84 | ||||
| Low | -2.49 | -2.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.